Robert M. Lorence

4.5k citations

51 papers · 3.7k indexed · 1 hit paper · h-index 29

Impact in

Oncology top 1%
- Colorectal Cancer Treatments and Studies
- CAR-T cell therapy research
- Lung Cancer Research Studies
- HER2/EGFR in Cancer Research
Genetics top 1%
- Virus-based gene therapy research

Papers in ⓘ

Pulmonary and Respiratory Medicine 18
- Lung Cancer Treatments and Mutations 18
Oncology 18
- HER2/EGFR in Cancer Research 7
- Lung Cancer Research Studies 6
- Peptidase Inhibition and Analysis 5
- Colorectal Cancer Treatments and Studies 5

Co-authors: Robert Walter (6 shared papers)Robert B. Gennis (7 shared papers)James Chih‐Hsin Yang (6 shared papers)Mark E. Peeples (5 shared papers)Kirk W. Reichard (5 shared papers)Keith W. Kelley (5 shared papers)Wu‐Chou Su (4 shared papers)Mehdi Shahidi (3 shared papers)
Journals: Journal of Clinical Oncology (7 papers)Journal of Biological Chemistry (6 papers)European Journal of Cancer (4 papers)JNCI Journal of the National Cancer Institute (3 papers)Journal of Thoracic Oncology (3 papers)
Partner nations: United States Taiwan Canada

In The Last Decade

Robert M. Lorence

49 papers receiving 3.6k citations

Hit Papers

align trajectories log scale

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial 2012 · 776 citations

Peers

Countries citing papers authored by Robert M. Lorence

Since Specialization

Citations

This map shows the geographic impact of Robert M. Lorence's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert M. Lorence with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert M. Lorence more than expected).

Fields of papers citing papers by Robert M. Lorence

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert M. Lorence. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert M. Lorence. The network helps show where Robert M. Lorence may publish in the future.

Co-authors

The 25 scholars most cited alongside Robert M. Lorence, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Robert M. Lorence Line = papers co-authored together Robert M. Lorence links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 51 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial The Lancet Oncology ·Vincent A. Miller, Vera Hirsh, Jacques Cadranel, Yuh-Min Chen, Keunchil Park, Sang-We Kim, Caicun Zhou, Wu‐Chou Su, Mengzhao Wang, Yan Sun, Dae Seog Heo, Lucio Crinò, Eng-Huat Tan, Tsu-Yi Chao, Mehdi Shahidi, Xiuyu Julie Cong, Robert M. Lorence, James Chih‐Hsin Yang Hit paper breakdown →	2012	776
2	Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial The Lancet Oncology ·James Chih‐Hsin Yang, Jin‐Yuan Shih, Wu‐Chou Su, Te‐Chun Hsia, Chun-Ming Tsai, Sai‐Hong Ignatius Ou, Chong‐Jen Yu, Gee‐Chen Chang, Ching-Liang Ho, Lecia V. Sequist, Arkadiusz Z. Dudek, Mehdi Shahidi, Xiuyu Julie Cong, Robert M. Lorence, Pan‐Chyr Yang, Vincent A. Miller	2012	332
3	Phase I Trial of Intravenous Administration of PV701, an Oncolytic Virus, in Patients With Advanced Solid Cancers Journal of Clinical Oncology ·Andrew L. Pecora, Naiyer A. Rizvi, Gary I. Cohen, Neal J. Meropol, Daniel H. Sterman, John L. Marshall, Stuart L. Goldberg, Peter Groß, James D. O’Neil, William S. Groene, M. Scot Roberts, Harvey Rabin, Michael K. Bamat, Robert M. Lorence	2002	314
4	Newcastle disease virus selectively kills human tumor cells Journal of Surgical Research ·Kirk W. Reichard, Robert M. Lorence, Christopher J. Cascino, Mark E. Peeples, Robert Walter, Michael B. Fernando, Hernan M. Reyes, John A. Greager	1992	199
5	LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. Journal of Clinical Oncology ·James Chih‐Hsin Yang, Martin Schüler, Nobuyuki Yamamoto, Kenneth J. O’Byrne, Vera Hirsh, Tony Mok, Sarayut Lucien Geater, Sergey Orlov, Chun‐Ming Tsai, Michael Boyer, Wu‐Chou Su, Jaafar Bennouna, Terufumi Kato, В. А. Горбунова, Ki Hyeong Lee, Riyaz Shah, Dan Massey, Robert M. Lorence, Mehdi Shahidi, Lecia V. Sequist	2012	136
6	Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration Cancer Letters ·Anan Phuangsab, Robert M. Lorence, Kirk W. Reichard, Mark E. Peeples, Robert Walter	2001	135
7	Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy. PubMed ·Robert M. Lorence, Burt Katubig, Kirk W. Reichard, Hernan M. Reyes, Anan Phuangsab, Madalena Sassetti, Robert Walter, Mark E. Peeples	1994	129
8	Newcastle Disease Virus as an Antineoplastic Agent: Induction of Tumor Necrosis Factor- and Augmentation of Its Cytotoxicity2 JNCI Journal of the National Cancer Institute ·Robert M. Lorence, P. A. Rood, Keith W. Kelley	1988	125
9	A Phase 1 Clinical Study of Intravenous Administration of PV701, an Oncolytic Virus, Using Two-Step Desensitization Clinical Cancer Research ·Scott A. Laurie, John C. Bell, Harold Atkins, Joanne Roach, Michael K. Bamat, James D. O’Neil, M. Scot Roberts, William S. Groene, Robert M. Lorence	2006	103
10	Complete Regression of Human Neuroblastoma Xenografts in Athymic Mice After Local Newcastle Disease Virus Therapy JNCI Journal of the National Cancer Institute ·Robert M. Lorence, Kirk W. Reichard, Burt Katubig, Hernan M. Reyes, Anan Phuangsab, B. R. Mitchell, Christopher J. Cascino, Robert Walter, Mark E. Peeples	1994	102
11	The pituitary gland is required for protection against lethal effects of Salmonella typhimurium. Proceedings of the National Academy of Sciences ·Carl K. Edwards, Libby M. Yunger, Robert M. Lorence, Robert Dantzer, Keith W. Kelley	1991	102
12	An Optimized Clinical Regimen for the Oncolytic Virus PV701 Clinical Cancer Research ·Sébastien J. Hotte, Robert M. Lorence, Hal W. Hirte, S. Polawski, Michael K. Bamat, James D. O’Neil, M. Scot Roberts, William S. Groene, Pierre Major	2007	98
13	Coulometric and spectroscopic analysis of the purified cytochrome d complex of Escherichia coli: evidence for the identification of "cytochrome a1" as cytochrome b595 Biochemistry ·Robert M. Lorence, John G. Koland, Robert B. Gennis	1986	95
14	Phase 1 Clinical Experience Using Intravenous Administration of PV701, an Oncolytic Newcastle Disease Virus Current Cancer Drug Targets ·Robert M. Lorence, M. Scot Roberts, James P. O’Neil, William S. Groene, Jeffrey S. Miller, Stephen N. Mueller, Michael K. Bamat	2007	93
15	In vivo administration of recombinant growth hormone or gamma interferon activities macrophages: enhanced resistance to experimental Salmonella typhimurium infection is correlated with generation of reactive oxygen intermediates Infection and Immunity ·Carl K. Edwards, Syed M. Ghiasuddin, Libby M. Yunger, Robert M. Lorence, Seán Arkins, Robert Dantzer, Keith W. Kelley	1992	80
16	Properties of a copper-containing cytochrome c1aa3 complex: a terminal oxidase of the extreme thermophile Thermus thermophilus HB8. Proceedings of the National Academy of Sciences ·J.A. Fee, Miles G. Choc, Karen L. Findling, Robert M. Lorence, Takamasa Yoshida	1980	79
17	Hypophysectomy Inhibits the Synthesis of Tumor Necrosis Factor α by Rat Macrophages: Partial Restoration by Exogenous Growth Hormone or Interferon γ* Endocrinology ·Carl K. Edwards, Robert M. Lorence, Diane Dunham, Seán Arkins, LIBBY M. YUNGER, John A. Greager, Robert Walter, Robert Dantzer, KEITH W. KELLEY	1991	73
18	Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation–Positive Advanced NSCLC: Findings From a Global Named Patient Use Program Journal of Thoracic Oncology ·Solange Peters, Alessandra Curioni‐Fontecedro, Hovav Nechushtan, Jin‐Yuan Shih, Wei‐Yu Liao, Oliver Gautschi, Vito Spataro, Mojca Unk, James Chih‐Hsin Yang, Robert M. Lorence, Philippe Carrière, A. Cseh, Gee‐Chen Chang	2018	66
19	Identification of subunit I as the cytochrome b558 component of the cytochrome d terminal oxidase complex of Escherichia coli. Journal of Biological Chemistry ·G N Green, Robert G. Kranz, Robert M. Lorence, R B Gennis	1984	63
20	Symptom and Quality of Life Benefit of Afatinib in Advanced Non–Small-Cell Lung Cancer Patients Previously Treated with Erlotinib or Gefitinib: Results of a Randomized Phase IIb/III Trial (LUX-Lung 1) Journal of Thoracic Oncology ·Vera Hirsh, J. Cadranel, Xiuyu Julie Cong, Diane L. Fairclough, Henrik W. Finnern, Robert M. Lorence, V. A. Miller, Michael Palmer, James Chih‐Hsin Yang	2013	61

About Robert M. Lorence

Robert M. Lorence is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, Genetics and Epidemiology, having authored 51 papers that have together received 3.7k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (18 papers), Virus-based gene therapy research (16 papers), Photosynthetic Processes and Mechanisms (10 papers), Virology and Viral Diseases (9 papers), HER2/EGFR in Cancer Research (7 papers), Lung Cancer Research Studies (6 papers), Peptidase Inhibition and Analysis (5 papers) and Colorectal Cancer Treatments and Studies (5 papers). The work is most often cited by research in Oncology (1.7k citations), Genetics (1.3k citations), Pulmonary and Respiratory Medicine (1.4k citations), Animal Science and Zoology (408 citations) and Molecular Biology (1.5k citations). Robert M. Lorence has collaborated with scholars based in United States, Taiwan and Canada. Frequent co-authors include Robert Walter, Robert B. Gennis, James Chih‐Hsin Yang, Mark E. Peeples, Kirk W. Reichard, Keith W. Kelley, Wu‐Chou Su, Mehdi Shahidi, Xiuyu Julie Cong and William S. Groene. Their work appears in journals such as Journal of Clinical Oncology, Journal of Biological Chemistry, European Journal of Cancer, JNCI Journal of the National Cancer Institute and Journal of Thoracic Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact